Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768831 | 1.00 | HIF1A (0.41) | HIF1AALDH1A1TSHRTP53HSD17B10 | |
| SCHEMBL17613231 | 1.00 | HIF1A (0.41) | HIF1AALDH1A1TSHRTP53HSD17B10 | |
| SCHEMBL17613220 | 1.00 | HIF1A (0.41) | HIF1AALDH1A1TSHRTP53HSD17B10 | |
| SCHEMBL11990606 | 1.00 | HIF1A (0.41) | HIF1AALDH1A1TSHRTP53HSD17B10 | |
| SCHEMBL3955608 | 0.96 | — | — | |
| SCHEMBL25779382 | 0.88 | HIF1A (0.33) | HIF1AALDH1A1 | |
| SCHEMBL24227372 | 0.86 | APP (0.33) | HIF1AMEN1KMT2A | |
| SCHEMBL24127592 | 0.86 | HIF1A (0.32) | HIF1A | |
| SCHEMBL9952291 | 0.86 | HIF1A (0.32) | HIF1A | |
| SCHEMBL14873888 | 0.86 | HIF1A (0.32) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961527-B2 | Reprogramming urokinase into an antibody-recruiting anticancer agent | YALE UNIVERSITY (US) | 2021-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961527-B2 | Reprogramming urokinase into an antibody-recruiting anticancer agent | PLAUR, CD47, CD14 | HIF1A 1726/4885ALDH1A1 3594/4885TSHR 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.